Literature DB >> 25361775

A homozygous splice-site mutation in CARS2 is associated with progressive myoclonic epilepsy.

Kerstin Hallmann1, Gábor Zsurka1, Susanna Moskau-Hartmann1, Janbernd Kirschner1, Rudolf Korinthenberg1, Ann-Kathrin Ruppert1, Ozkan Ozdemir1, Yvonne Weber1, Felicitas Becker1, Holger Lerche1, Christian E Elger1, Holger Thiele1, Peter Nürnberg1, Thomas Sander1, Wolfram S Kunz2.   

Abstract

OBJECTIVE: We report a consanguineous family with 2 affected individuals whose clinical symptoms closely resembled MERRF (myoclonus epilepsy with ragged red fibers) syndrome including severe myoclonic epilepsy, progressive spastic tetraparesis, progressive impairment of vision and hearing, as well as progressive cognitive decline.
METHODS: After excluding the presence of pathogenic mitochondrial DNA mutations, whole-exome sequencing of blood DNA from the index patient was performed. Detected homozygous mutations and their cosegregation were confirmed by Sanger sequencing. CARS2 (cysteinyl-tRNA synthetase 2, mitochondrial) messenger RNA analysis was performed by reverse transcription PCR and sequencing.
RESULTS: We identified a homozygous c.655G>A mutation in the CARS2 gene cosegregating in the family. The mutation is localized at the last nucleotide of exon 6 and thus is predicted to cause aberrant splicing. Analysis of the CARS2 messenger RNA showed that the presence of the mutation resulted in removal of exon 6. This leads to an in-frame deletion of 28 amino acids in a conserved sequence motif of the protein involved in stabilization of the acceptor end hairpin of tRNA(Cys).
CONCLUSION: CARS2 is a novel disease gene associated with a severe progressive myoclonic epilepsy most resembling MERRF syndrome.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25361775     DOI: 10.1212/WNL.0000000000001055

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

Review 1.  Emerging mechanisms of aminoacyl-tRNA synthetase mutations in recessive and dominant human disease.

Authors:  Rebecca Meyer-Schuman; Anthony Antonellis
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

Review 2.  Movement disorders in mitochondrial disease.

Authors:  Roula Ghaoui; Carolyn M Sue
Journal:  J Neurol       Date:  2018-01-06       Impact factor: 4.849

Review 3.  Human aminoacyl-tRNA synthetases in diseases of the nervous system.

Authors:  Jana Ognjenović; Miljan Simonović
Journal:  RNA Biol       Date:  2017-06-30       Impact factor: 4.652

4.  Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.

Authors:  Ewen W Sommerville; Yi Shiau Ng; Charlotte L Alston; Cristina Dallabona; Micol Gilberti; Langping He; Charlotte Knowles; Sophie L Chin; Andrew M Schaefer; Gavin Falkous; David Murdoch; Cheryl Longman; Marianne de Visser; Laurence A Bindoff; John M Rawles; John C S Dean; Richard K Petty; Maria E Farrugia; Tobias B Haack; Holger Prokisch; Robert McFarland; Douglass M Turnbull; Claudia Donnini; Robert W Taylor; Gráinne S Gorman
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

Review 5.  When a common biological role does not imply common disease outcomes: Disparate pathology linked to human mitochondrial aminoacyl-tRNA synthetases.

Authors:  Ligia Elena González-Serrano; Joseph W Chihade; Marie Sissler
Journal:  J Biol Chem       Date:  2019-01-15       Impact factor: 5.157

6.  Novel Compound Heterozygous Mutations Expand the Recognized Phenotypes of FARS2-Linked Disease.

Authors:  Melissa A Walker; Kyle P Mohler; Kyle W Hopkins; Derek H Oakley; David A Sweetser; Michael Ibba; Matthew P Frosch; Ronald L Thibert
Journal:  J Child Neurol       Date:  2016-04-19       Impact factor: 1.987

Review 7.  Persulfide synthases that are functionally coupled with translation mediate sulfur respiration in mammalian cells.

Authors:  Shigemoto Fujii; Tomohiro Sawa; Hozumi Motohashi; Takaaki Akaike
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

8.  A Novel Homozygous YARS2 Mutation in Two Italian Siblings and a Review of Literature.

Authors:  Anna Ardissone; Eleonora Lamantea; Jade Quartararo; Cristina Dallabona; Franco Carrara; Isabella Moroni; Claudia Donnini; Barbara Garavaglia; Massimo Zeviani; Graziella Uziel
Journal:  JIMD Rep       Date:  2015-02-01

9.  Structural modeling of tissue-specific mitochondrial alanyl-tRNA synthetase (AARS2) defects predicts differential effects on aminoacylation.

Authors:  Liliya Euro; Svetlana Konovalova; Jorge Asin-Cayuela; Már Tulinius; Helen Griffin; Rita Horvath; Robert W Taylor; Patrick F Chinnery; Ulrike Schara; David R Thorburn; Anu Suomalainen; Joseph Chihade; Henna Tyynismaa
Journal:  Front Genet       Date:  2015-02-06       Impact factor: 4.599

10.  Imputation and Reanalysis of ExomeChip Data Identifies Novel, Conditional and Joint Genetic Effects on Parkinson's Disease Risk.

Authors:  Linduni M Rodrigo; Dale R Nyholt
Journal:  Genes (Basel)       Date:  2021-05-04       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.